LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular is well positioned because it combines durable pricing power with niche products that typically represent only 5-10% of a procedure’s cost, supporting high-single-digit pricing tailwinds and helping lift gross margin to 72.7% in 1Q26. The company also delivered 10% organic revenue growth, 36% worldwide Artegraft growth, 33.5% higher adjusted EBITDA, and 42% EPS growth, while FY/26 guidance now implies about 12% revenue growth and roughly 29% operating margin, or 300 bps of year-over-year improvement. Its expansion into international markets, continued sales force buildout, and strong cash generation, with $367.2 million in cash and marketable securities plus a $100 million repurchase authorization, further reinforce the positive outlook.

LeMaitre Vascular is facing a cautious fundamental setup because its growth remains dependent on a limited acquisition pipeline while sales-force expansion and international execution add near-term cost and complexity. Revenue of $66.6 million in 1Q slightly missed estimates, and although sales rose 11% as reported and 10% organically, the Americas still underperformed expectations at $41.6 million, leaving the company reliant on broader operational leverage to justify growth. Regulatory risk also weighs heavily, since sales outside the U.S. have represented 40% of total revenues in the past and the company must secure and maintain MDR CE marks through December 2027 and December 2028 for certain products.